SCHEMBL792919

SCHEMBL792919

O=S(=O)(NCCCCN1CCN(c2cccc3[nH]ccc23)CC1)c1ccc(F)cc1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 13/20 0.67
DRD2 P14416 10/20 0.67
DRD3 P35462 5/20 0.67
ADRA1A P35348 3/20 0.67
DRD4 P21917 3/20 0.67
ADRA1D P25100 2/20 0.67
ADRA1B P35368 2/20 0.67
HTR7 P34969 9/20 0.54
SLC6A4 P31645 4/20 0.54
HTR2A P28223 3/20 0.54
HTR2B P41595 1/20 0.54
KCNH2 Q12809 1/20 0.54
HTR2C P28335 2/20 0.51
ADRA2A P08913 3/20 0.49
HTR6 P50406 3/20 0.49
FAAH O00519 1/20 0.49
CNR1 P21554 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL791263 0.91 DRD2 (0.58) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL15064185 0.91 DRD2 (0.55) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL793473 0.90 HTR1A (0.54) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL15064226 0.90 HTR7 (0.55) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL792847 0.86 DRD2 (0.67) HTR1ADRD2DRD3ADRA1AHTR7
SCHEMBL792428 0.86 HTR7 (0.56) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL793048 0.84 DRD2 (0.51) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL792851 0.84 HTR1A (0.54) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL792581 0.84 HTR7 (0.56) HTR1ADRD2DRD3ADRA1ADRD4
SCHEMBL790906 0.84 HTR1A (0.66) HTR1ADRD2DRD3ADRA1ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP claimed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US claimed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO claimed
US-9120767-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z.O.O. (PL) 2015-09-01 US disclosed
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2014-11-13 US disclosed
US-8822517-B2 Arylosulfonamides for the treatment of CNS diseases ADAMED SP. Z O.O. (PL) 2014-09-02 US disclosed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 EP disclosed
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z.O.O. (PL) 2013-07-04 US disclosed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336200-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS HTR1A 1354/4885DRD2 3216/4885DRD3 3561/4885
US-20130172365-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ARSA, PMP22, STS HTR1A 1354/4885DRD2 3216/4885DRD3 3561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.